Monthly
US$200
Billed every month
Bromocriptine Mesilate Tablets(甲磺酸溴隐亭片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders4View records ↓
Under-review filings5View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers7View records ↓
API companies with A status2View records ↓
Chemical-drug catalogue
Loaded records: 4 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 3 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20265621 | 2026/08/18 | 2.5mg(按C32H40BrN5O5计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都瑞尔医药科技有限公司 | 杭州民生药业股份有限公司 | 国药准字H20256276 | 2025/12/16 | 2.5mg（按C32H40BrN5O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州沐源生物医药科技有限公司 | 华益药业科技（安徽）有限公司 | 国药准字H20256191 | 2025/12/09 | 2.5mg（按C32H40BrN5O5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Future Health Pharma GmbH | Novartis Farma S.P.A. | H20160030 | 1995/08/04 | 2.5mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 7 distinct approval numbers and 6 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京福元医药股份有限公司 | 国药准字H20265621 | 2.5mg(按C₃₂H₄₀BrN₅O₅计) | Category B (乙) | XG02CBX177A001010100177 | NHSA |
| Gedeon Richter Plc. | H20160170 | 2.5mg | Category B (乙) | XG02CBX177A001010179164 | NHSA |
| Bridging Pharma GmbH | 国药准字HJ20160030 | 2.5mg(按C₃₂H₄₀BrN₅O₅计) | Category B (乙) | XG02CBX177A001010180481 | NHSA |
| 江苏诚康药业有限公司 | 国药准字H20266180 | 2.5mg(按C₃₂H₄₀BrN₅O₅计) | Category B (乙) | XG02CBX177A001010182219 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20256191 | 2.5mg(按C₃₂H₄₀BrN₅O₅计) | Category B (乙) | XG02CBX177A001010184135 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20256276 | 2.5mg(按C₃₂H₄₀BrN₅O₅计) | Category B (乙) | XG02CBX177A001010184534 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20265621 | 2.5mg(按C₃₂H₄₀BrN₅O₅计) | Category B (乙) | XG02CBX177A001010200177 | NHSA |
| Gedeon Richter Plc. | 国药准字HJ20160170 | 2.5mg | Category B (乙) | XG02CBX177A001010279164 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20265621 | 2.5mg(按C₃₂H₄₀BrN₅O₅计) | Category B (乙) | XG02CBX177A001010300177 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 5 filings and 5 distinct first applicants.
Generic 5
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 株洲千金药业股份有限公司;湖南千金湘江药业股份有限公司 | CYHS2601890 | Generic | 2026/08/04 | Not stated by source | CDE |
| 广州大光制药有限公司 | CYHS2601761 | Generic | 2026/07/22 | Not stated by source | CDE |
| 河北龙海药业股份有限公司 | CYHS2601696 | Generic | 2026/07/16 | Not stated by source | CDE |
| 郑州泰丰制药有限公司 | CYHS2503478 | Generic | 2025/09/20 | Not stated by source | CDE |
| 浙江泰利森药业有限公司 | CYHS2503148 | Generic | 2025/08/27 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 株洲千金药业股份有限公司;湖南千金湘江药业股份有限公司 | CYHS2601890 | Generic | 2026/08/04 | Not stated by source | CDE |
| 广州大光制药有限公司 | CYHS2601761 | Generic | 2026/07/22 | Not stated by source | CDE |
| 河北龙海药业股份有限公司 | CYHS2601696 | Generic | 2026/07/16 | Not stated by source | CDE |
API registrations
Non-component matches: 2 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 甲磺酸溴隐亭 | 四川仁安药业有限责任公司 | Y20250000692 | I | Exact ingredient | 2025/07/14 | CDE |
| 甲磺酸溴隐亭 | CURIA ITALY S.R.L. | Y20230000473 | A | Exact ingredient | 2026/07/13 | CDE |
| 甲磺酸溴隐亭 | TAPI Czech Industries s.r.o. | Y20210000853 | A | Exact ingredient | 2025/05/08 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03Marketing application approved
湖南明瑞制药股份有限公司
CYHS2502310 · 国药准字H20266473
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 87 ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Bromocriptine Mesilate Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy